Peptide · Weight & body composition
AOD-9604 is a fragment of human growth hormone studied for fat metabolism without the full anabolic effects of GH.
AOD-9604 is a fragment of human growth hormone studied for fat metabolism without the full anabolic effects of GH.
AOD-9604 is a synthetic 16-amino-acid peptide corresponding to residues 176–191 of the human growth hormone molecule. The fragment was designed to retain the lipolytic (fat-burning) activity of HGH while removing the growth-promoting and glucose-impairing activity. The mechanism is thought to involve direct stimulation of fat cell lipolysis without IGF-1 elevation.
Limited clinical evidence for body-composition effects in humans.
Compounded — not FDA-approved.
Common protocols: 250–500 mcg subcutaneous daily, often dosed in the morning before exercise or fasted state. Cycles of 8–12 weeks are typical.
Dosing in research and clinical-use contexts varies. Specific protocols should always be set by a prescribing clinician, not by patient-direct sources.
Generally well-tolerated in available data. Reported side effects: injection-site irritation, occasional headache. Long-term safety is not well-characterized.
Sometimes layered with growth-hormone secretagogues (ipamorelin/CJC-1295) or tesamorelin for additive body composition effects. Often used alongside dietary interventions and resistance training.
Most peptides discussed on this page are compounded products requiring a prescription from a licensed clinician. Reputable telehealth peptide programs include physician-led oversight, accredited compounding pharmacies, and clear regulatory framing. For weight-management GLP-1 programs, see our provider reviews.
AOD-9604 is a fragment of human growth hormone studied for fat metabolism without the full anabolic effects of GH.
Compounded — not FDA-approved.
Uses include: Fat-loss adjunct (research). This is research and clinical-use context, not a recommendation. Always work with a licensed clinician.
Limited clinical evidence for body-composition effects in humans.
Reported dosing: 300–500 mcg subcutaneous daily. Actual dosing should always be determined by your prescribing clinician, not by online sources.
Clinical evidence is limited. The marketing claims often outpace the evidence. Patients should set realistic expectations and use AOD-9604 as one component of a broader weight-management approach, not a standalone solution.
No. AOD-9604 is a fragment of HGH that retains the lipolytic activity but lacks the growth-promoting effects. It does not raise IGF-1.